Analysis of mean annualised rate of moderate and/or severe exacerbations in the unpooled intention-to-treat population at weeks 1 to 52
| FF/VI 100/25 µg plus | FF/VI 200/25 µg plus | |||||
| No UMEC | UMEC 31.25 µg | UMEC 62.5 µg | No UMEC | UMEC 31.25 µg | UMEC 62.5 µg | |
| Subjects n | 407 | 405 | 406 | 406 | 404 | 408 |
| Mean annualised moderate and/or severe exacerbations rate | 0.87 (0.73–1.04) | 0.76 (0.64–0.92) | 0.68 (0.56–0.82) | 0.57 (0.47–0.69) | 0.61 (0.50–0.74) | 0.55 (0.45–0.67) |
| FF/UMEC/VI versus FF/VI | Ref. | 1.01 (0.72–1.42), p=0.96 | 1.07 (0.76–1.50), p=0.69 | Ref. | 0.98 (0.66–1.45), p=0.93 | 0.88 (0.60–1.31), p=0.54 |
Data are presented as rate ratio (95% CI), unless otherwise stated. The p-values are not adjusted for multiplicity.